What is Genomines?
Genomines is at the forefront of sustainable mining innovation, genetically enhancing metal hyperaccumulator plants. These specialized plants are engineered to efficiently extract and produce bio-sourced metals, thereby mitigating the environmental impact traditionally associated with mining operations. The company's approach offers a novel solution to resource acquisition, aligning with global demands for greener industrial practices and circular economy principles.
How much funding has Genomines raised?
Genomines has raised a total of $45M across 1 funding round:
Series A
$45M
Series A (2025): $45M with participation from DeepTech & Climate Fonds, Elemental Impact, Alphatech, Lowercarbon Capital, Teampact.ventures, Hyundai Motor Group, Forbion, and Engine Ventures
Key Investors in Genomines
DeepTech & Climate Fonds
DeepTech & Climate Fonds (DTCF) is a venture capital fund focused on long-term investments in early growth ventures across Germany and Europe, specializing in DeepTech and ClimateTech with investments ranging from 5 to 50 million EUR.
Lowercarbon Capital
Lowercarbon Capital backs companies focused on reducing CO2 emissions and removing carbon from the atmosphere, aiming to support climate-healing technologies.
Engine Ventures
Engine Ventures is a venture firm that invests in Tough Tech founders addressing global challenges through breakthrough technologies, providing capital and operational expertise for scaling.
What's next for Genomines?
With this major strategic investment, Genomines is poised to accelerate its research and development, scale its cultivation and extraction processes, and expand its market reach. The substantial capital infusion is expected to fuel further technological advancements in plant genetics and bio-mining techniques, solidifying Genomines' leadership in the sustainable materials sector. Future endeavors will likely focus on forging strategic partnerships and optimizing production to meet the growing demand for environmentally responsible metal sourcing.
See full Genomines company page
